In-vitro antiplatelet activity of silver nanoparticles synthesized using the microorganism *Gluconobacter roseus*: AFM based study

R.Navanietha krishnaraj and Sheela Berchmans* DOI: 10.1039/b000000x

SUPPLEMENTARY INFORMATION

Determination of nanoparticle concentration

The dosage of the nanoparticles to be administered was calculated by a method which has been previously reported. ^{22,23} The calculation was made as follows:

The average number of atoms per nanoparticles, N was calculated using the formula below: Number of atoms in a nanoparticle, $N_A = V_2/V_1$ where V_1 is the volume of a silver atom and V_2 is the average volume of a AgNPs.

 $V_1 = 4\pi (r)^3/3 = [4x3.14x(144pm)^3]/3$ = 1.250x10⁻²⁹ m³ $V_2 = a^3 = (10x10^{-9})^3 = 1x10^{-24}m^3$

Number of atoms in 1 nanoparticle = 8×10^4 atoms.

Number of atoms in 1mM solution (broth)

 $=1 \times 10^{-3} \times 6.023 \times 10^{23} = 6.023 \times 10^{20}$ atoms.

Number of nanoparticles in the broth

= Total atoms/ N_A

 $=6.023 \times 10^{20} / 80000$

 $=7.5287 \times 10^{15}$ nanoparticles.

Concentration of nanoparticle, C_{NP}

= Number of nanoparticles/Avagadros number = $7.5287 \times 10^{15}/6.023 \times 10^{23}$

 $= 1.2499 \times 10^{-8} \, \text{nmol/dm}^3$

 $= 12.499 \times 10^{-9} \text{ nmol/dm}^3$

400, 800, 1200, 1600 and 2000 μl of the sample was taken as drug for 5 ml of PRP. So,the different dosages were as follows.

Concentration in 0.4mL

= 0.4mLx 12.499 nM/5.4mL=0.9 nM.

Concentration in 0.8 mL

= 0.8 mLx 12.499 nM / 5.8 mL = 1.7 nM.

Concentration in 1.2mL

= 1.2 mLx 12.499 nM/6.2 mL = 2.4 nM.

Concentration in 1.6mL

= 1.6mLx12.499 nM/6.6mL=3.0nM.

Concentration in 2mL = 2.0mLx12.499nM/7mL=3.5nM.

Fig.S1: Particle size distribution of the *Gluconobacter roseus* synthesized AgNPs obtained from DLS measurement.




Fig.S2: Zeta potential distribution of the Gluconobacter roseus synthesized AgNPs.




Fig.S3: EDAX spectrum of the *Gluconobacter roseus* synthesized AgNPs.




Fig.S4(A) Topographic images of platelets pretreated with ADP.




Fig.S4(B) Topographic images of AgNP treated platelets pretreated with ADP.

